Abstract
Iron chelators have been widely used to remove excess toxic iron from patients with secondary iron overload. However, small molecule-based iron chelators can cause adverse side effects such as infection, gastrointestinal bleeding, kidney failure, and liver fibrosis. Here we report renal clearable nanochelators for iron overload disorders. First, after a single-dose intravenous injection, the nanochelator shows favorable pharmacokinetic properties, such as kidney-specific biodistribution and rapid renal excretion (>80% injected dose in 4 h), compared to native deferoxamine (DFO). Second, subcutaneous (SC) administration of nanochelators improves pharmacodynamics, as evidenced by a 7-fold increase in efficiency of urinary iron excretion compared to intravenous injection. Third, daily SC injections of the nanochelator for 5 days to iron overload mice and rats decrease iron levels in serum and liver. Furthermore, the nanochelator significantly reduces kidney damage caused by iron overload without demonstrating DFO's own nephrotoxicity. This renal clearable nanochelator provides enhanced efficacy and safety.
Introduction
Iron is essential for life, but its excess is highly toxic. Patients with conditions like hereditary hemochromatosis or those requiring frequent blood transfusions suffer from "iron overload," where excess iron catalyzes the production of harmful free radicals. This leads to severe organ failure, particularly in the liver and heart.
The current gold-standard treatment, deferoxamine (DFO), is limited by an incredibly short half-life and significant side effects, including potential kidney failure at high doses. While larger nanoparticle-based chelators have been explored, they often become trapped in the liver or spleen, potentially worsening organ damage. To solve this, researchers developed "nanochelators"—ultrasmall nanoparticles designed to stay in circulation longer than DFO while remaining small enough to be safely cleared by the kidneys.
Design and Synthesis
The researchers synthesized a series of renal clearable nanochelators (DFO-NPs) using a modular approach. They utilized a biodegradable $\epsilon$-poly-L-lysine (EPL) backbone and engineered the surface to be zwitterionic (neutral) to prevent non-specific tissue binding. DFO moieties were then conjugated to this backbone. By maintaining a hydrodynamic diameter between 5.5 and 6.5 nm—just below the kidney's filtration threshold—the team ensured the particles could effectively capture iron in the blood before being flushed out in urine.
Pharmacokinetics and Biodistribution
The nanochelators demonstrated exceptional pharmacokinetic properties. Real-time near-infrared (NIR) fluorescence imaging in mice confirmed that the particles specifically accumulate in the kidneys and bladder shortly after injection, verifying the intended renal clearance pathway.
Quantitative analysis showed that over 80% of the injected dose was excreted through the kidneys within 4 hours. Compared to native DFO, the nanochelators exhibited a significantly improved blood half-life, allowing for more sustained iron chelation in the extracellular space.
Therapeutic Efficacy and Safety
A major breakthrough was the discovery that subcutaneous (SC) administration was far more effective than intravenous (IV) injection. The SC site acts as a slow-release reservoir, maintaining a steady concentration of chelators in the blood. This approach resulted in a 7-fold increase in the efficiency of urinary iron excretion.
In iron-overloaded animal models, 5 days of SC treatment restored serum iron levels to near-normal and significantly reduced iron deposits in the liver. Crucially, the nanochelators showed no nephrotoxicity. In fact, they actively reduced the kidney damage caused by the iron overload itself, providing a safer alternative to traditional small-molecule therapies.
Conclusion
Renal clearable nanochelators represent a promising new strategy for treating iron overload. By combining precise size control for renal clearance with a biocompatible delivery system, this technology offers enhanced therapeutic efficacy and a superior safety profile compared to current standards of care. Future work may focus on long-term studies and clinical translation to human trials.
Summary updated